Rafi Mohammad brings over a decade of experience in pharmaceutical development, with expertise in formulation and delivery of gene therapeutics, siRNA, antibody, and protein therapeutics. He is also a pioneer in targeted nano medicine formulations for metastatic cancers and has published research on in vivo delivery of transcription factors for hepatocyte targeting in 'Nature Materials.' Mohammad has led formulation, drug product device compatibility, and process development for biologics in clinical trials. He has collaborated with internal stakeholders and external CMOs, and has been granted five patents in drug formulation and targeting.

Mohammad has an extensive educational background in pharmacy, biotechnology, internal medicine, and business management. He has held various positions across multiple prestigious organizations such as Bayer, UC Berkeley, and Novartis.

Keywords: Pharmaceutical Development, Gene Therapeutics, Formulation Development, Targeted Nano Medicine, Biologics, Drug Formulation, Targeted Drug Delivery, Cancer Nanomedicine, Preclinical Pharmacology, Assay Development, Pharmacokinetics/Pharmacodynamics (PK/PD), Cancer Imaging, Polymeric Micelles, Targeted Cancer Therapeutics, Targeted Gold-Phage Nanotechnology, Bioactive Proteins, Vaccine Nanoparticles, Research & Development.